Scilex Holding Company
NASDAQ:SCLXDrug Manufacturers - General
-$0.17 today
- Market cap
- $53.83M
- Beta
- 1.71
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.90
Volume 0.00M
Average 0.13M
SCLX Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Scilex Holding CompanyNASDAQ: SCLX
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities rises 166.2% from a year ago
Other non-current liabilities stood at $27.66M at the end of Q1 FY2026, up 166.2% from a year earlier and down 47.6% from the prior quarter. Over 3 fiscal years it compounded at +122.7% a year.
Context
- Other non-current liabilities amounted to 9.4% of total assets at the end of Q1 FY2026, down 3.7 pp from a year earlier.
- Other non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +166.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 52.81M USD
- Year-over-year change
- +152.6%
- 4-year CAGR
- +14.7%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.81M | +152.6% |
| FY2024 | 2024-12-31 | 20.91M | +355.3% |
| FY2023 | 2023-12-31 | 4.59M | -4.0% |
| FY2022 | 2022-12-31 | 4.78M | -84.3% |
| FY2021 | 2021-12-31 | 30.51M | — |
Other Non-current Liabilities vs competitors
How SCLX compares with its peers on the latest reported figures
- SCLX's Mar 2026 other non-current liabilities of $27.66M is the 2nd highest of the 9 companies compared; the peer median is $13K.
- Its year-over-year change of +166.2% is the 2nd highest of 7, against a peer median of -58.0%.
- Other non-current liabilities amounts to 9.4% of total assets for SCLX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | Mar 2026 | $77.35M | +310.5% | — | 115.8% |
| Mar 2026 | $27.66M | +166.2% | +122.7% | 9.4% | |
| Mar 2026 | $1.77M | +27.0% | +31.8% | 0.7% | |
| Mar 2026 | $247K | -99.9% | -89.4% | 0.1% | |
| Mar 2026 | $26K | -16.1% | -70.8% | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
CTORCitius Oncology, Inc. | Mar 2026 | $0 | -100.0% | +69.1% | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SCLX) | $13K | -58.0% | -19.5% | 0.0% | |
Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.34M | 2.18M | 3.92M | 3.27M | 4.96M |
| Short-term Investments | 0 | 0 | 0 | 0 | 6.03M |
| Net Receivables | 14.27M | 21.24M | 34.6M | 26.44M | 15.24M |
| Inventory | 2.56M | 1.38M | 4.21M | 2.44M | 4.79M |
| Other Current Assets | 1.83M | 0 | 0 | 9.4M | 7.34M |
| Total Current Assets | 23M | 29.61M | 46.78M | 41.55M | 38.36M |
| Property, Plant & Equipment (Net) | 2.11M | 1.9M | 3.67M | 2.93M | 28.42M |
| Goodwill | 13.48M | 13.48M | 13.48M | 13.48M | 13.48M |
| Intangible Assets | 38.8M | 40.59M | 36.49M | 32.45M | 59.09M |
| Long-term Investments | 0 | 0 | 808K | 2.42M | 1M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 538K | 944K | 89K | 119K | 224.64M |
| Total Non-current Assets | 54.93M | 56.92M | 54.53M | 51.41M | 326.62M |
| Total Assets | 77.93M | 86.53M | 101.31M | 92.95M | 364.98M |
| Account Payables | 4.28M | 8.45M | 40.95M | 52.62M | 86.27M |
| Short-term Debt | 57.56M | 0 | 108.43M | 34.88M | 92.28M |
| Tax Payables | 0 | 0 | 1.45M | 876K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 264K | 491K | 169.04M | 301.79M |
| Total Current Liabilities | 169.42M | 44.84M | 250.38M | 259.64M | 483.65M |
| Long-term Debt | 95.54M | 0 | 17.04M | 845K | 27.12M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 5.19M | 0 | 0 | 2.69M | 0 |
| Other Non-current Liabilities | 30.51M | 4.78M | 4.59M | 20.91M | 52.81M |
| Total Non-current Liabilities | 132.39M | 5.45M | 23.87M | 25.96M | 93.08M |
| Total Liabilities | 301.81M | 50.29M | 274.25M | 285.59M | 576.73M |
| Common Stock | 13K | 14K | 16K | 24K | 1K |
| Retained Earnings | (352.55M) | (375.91M) | (490.25M) | (563.05M) | (921.79M) |
| Accumulated OCI | 0 | (0) | 0 | 6.32M | (5.8M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | (3.97M) |
| Total Equity | (223.88M) | 36.24M | (172.94M) | (192.64M) | (211.75M) |
| Total Debt | 154.75M | 1.41M | 128.46M | 37.96M | 132.54M |
| Net Debt | 150.41M | (774K) | 124.54M | 34.69M | 127.59M |
Scilex Holding Company
NASDAQ:SCLX
Intrinsic Alpha fair value
Locked
Current Price
$6.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.